Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL
Blood · 04.07.2024 · 144 (1) · 61-73
DOI: 10.1182/blood.2024023930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 04.07.2024. Verfasst von Yaqi Zhao und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: Inotuzumab Ozogamicin, Sialic Acid Binding Ig-like Lectin 2, Drug Resistance, Neoplasm, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the genomic determinants of the response and resistance to InO. Pre- and post-InO–treated patient samples were analyzed by whole genome, exome, and/or transcriptome sequencing. Acquired CD22 mutations were observed in 11% (3/27) of post-InO-relapsed tumor samples, but not in refractory samples (0/16). There were multiple CD22 mutations per sample and the mechanisms of CD22 escape included epitope loss (protein truncation and destabilization) and epitope alteration. Two CD22 mutant cases were post-InO hyper-mutators resulting from error-prone DNA damage repair (nonhomologous/alternative end-joining repair, or mismatch repair deficiency), suggesting that hypermutation drove escape from CD22-directed therapy. CD22-mutant relapses occurred after InO and subsequent hematopoietic stem cell transplantation (HSCT), suggesting that InO eliminated the predominant clones, leaving subclones with acquired CD22 mutations that conferred resistance to InO and subsequently expanded. Acquired loss-of-function mutations in TP53, ATM, and CDKN2A were observed, consistent with a compromise of the G1/S DNA damage checkpoint as a mechanism for evading InO-induced apoptosis. Genome-wide CRISPR/Cas9 screening of cell lines identified DNTT (terminal deoxynucleotidyl transferase) loss as a marker of InO resistance. In conclusion, genetic alterations modulating CD22 expression and DNA damage response influence InO efficacy. Our findings highlight the importance of defining the basis of CD22 escape and eradication of residual disease before HSCT. The identified mechanisms of escape from CD22-targeted therapy extend beyond antigen loss and provide opportunities to improve therapeutic approaches and overcome resistance. These trials were registered at www.ClinicalTrials.gov as NCT01134575, NCT01371630, and NCT03441061.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
- Center of Excellence for Leukemia Studies, St. Jude Children's Research Hospital, Memphis, TN.
- Department of Leukemia, MD Anderson Cancer Center, Houston, TX.
- Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN.
- Department of Hematopathology, MD Anderson Cancer Center, Houston, TX.
- Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN.
ORCID-Profile: Yaqi Zhao, Nicholas J Short, Ti-Cheng Chang, Pankaj S Ghate, Walid Macaron, Beenu Thakral, Joseph Khoury, Yiping Fan, Lewis F Nasr, Kathryn G Roberts, Marina Konopleva, Charles G Mullighan
Förderung
- NCI NIH HHS
Zitieren
APA
Zhao, Y., Short, N. J., Kantarjian, H. M., Chang, T. C., Ghate, P. S., Qu, C., Macaron, W., Jain, N., Thakral, B., Phillips, A. H., Khoury, J., Garcia-Manero, G., Zhang, W., Fan, Y., Yang, H., Garris, R. S., Nasr, L. F., Kriwacki, R. W., Roberts, K. G., …, & Mullighan, C. G. (2024). Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood, 144(1), 61-73. https://doi.org/10.1182/blood.2024023930
Vancouver
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, et al. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024;144(1):61-73. doi:10.1182/blood.2024023930
BibTeX
@article{Zhao2024,
author = {Zhao, Yaqi and Short, Nicholas J and Kantarjian, Hagop M and Chang, Ti-Cheng and Ghate, Pankaj S and Qu, Chunxu and Macaron, Walid and Jain, Nitin and Thakral, Beenu and Phillips, Aaron H and Khoury, Joseph and Garcia-Manero, Guillermo and Zhang, Wenchao and Fan, Yiping and Yang, Hui and Garris, Rebecca S and Nasr, Lewis F and Kriwacki, Richard W and Roberts, Kathryn G and Konopleva, Marina and Jabbour, Elias J and Mullighan, Charles G},
title = {Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL},
journal = {Blood},
year = {2024},
volume = {144},
number = {1},
pages = {61--73},
doi = {10.1182/blood.2024023930}
}
EUVIMED